Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Srinivas Rao | M | 55 |
Kures, Inc.
 Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 5 jaar |
| Jonathan Sporn | M | - |
Gilgamesh Pharmaceuticals, Inc.
 Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Andrew Carry Kruegel | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY.
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
| Jeff Witkin | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Mike Cunningham | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Errol de Souza | M | 70 |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
| Dakin Sloss | M | 33 |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | 2 jaar |
| Chad E. Beyer | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 2 jaar |
| Phil Skolnick | M | 77 |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Nicholas Haft | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
| Kevin T. Murphy | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Amy Kruse | F | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
| Robert Berman | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 13 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Dalibor Sames
- Persoonlijk netwerk
